Fate can be altered
Discovering and developing first-in-class small molecule drugs for improved treatment of diseases with significant clinical need.More info More info
To become a leading biotechnology company, globally recognized for discovering and developing breakthrough small molecule drugs acting on unexplored protein targets and novel RNAMore info More info
Molecure’s exceptional in-house medicinal chemistry, biology and discovery capabilities allied to novel target biology gained from leading universities worldwide has enabled us to create a broad pipeline of drug candidates targeting unique and unexplored protein targets, as well as a cutting-edge small molecule mRNA targeting discovery platform.Discover our pipeline Discover our pipeline
On the 28th March 2022, OncoArendi changed its name to Molecure
Molecure Announces Full Year Financial 2022 Results – A Year of Significant Progress
Invitation to investor meeting 5th April 2023, 2:00 pm (CET)
Molecure announces first patient dosed in Phase I trial with novel, first-in-class dual arginase inhibitor OATD-02 for the treatment of cancer
People are the foundation of Molecure’s success. Our scientists are the creators of the best ideas for the multiple new small molecule medicines that are invented in the laboratories. The Molecure team works together to discover the therapies needed to improve the treatment of previously incurable diseases.
It is this unified goal that guides us every day. We are inspired by science, we discover and create. For us, work is a passion.